Consensus $4.91. Raises FY26 free cash flow view to $200M-$220M from $170M-$210M. Backs FY26 adjusted operating margin view 26%-27%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- HAE Upcoming Earnings Report: What to Expect?
- Balancing Plasma Strength Against Vascular Closure Uncertainty: Maintaining a Neutral (Hold) View on Haemonetics
- Orchestra BioMed to receive up to $21M in proceeds from Vivasure acquisition
- Haemonetics price target raised to $93 from $90 at Barrington
- Haemonetics acquires Vivasure to expand structural heart portfolio